These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

392 related items for PubMed ID: 21804375

  • 1. Randomized comparison of two nonbismuth-containing rescue therapies for Helicobacter pylori.
    Hu TH, Chuah SK, Hsu PI, Wu DC, Tai WC, Chiu YC, Wu KL, Kuo CM, Hu ML.
    Am J Med Sci; 2011 Sep; 342(3):177-81. PubMed ID: 21804375
    [Abstract] [Full Text] [Related]

  • 2. Randomized comparison of two non-bismuth-containing second-line rescue therapies for Helicobacter pylori.
    Chuah SK, Hsu PI, Chang KC, Chiu YC, Wu KL, Chou YP, Hu ML, Tai WC, Chiu KW, Chiou SS, Wu DC, Hu TH.
    Helicobacter; 2012 Jun; 17(3):216-23. PubMed ID: 22515360
    [Abstract] [Full Text] [Related]

  • 3. The efficacy of second-line anti-Helicobacter pylori therapy using an extended 14-day levofloxacin/amoxicillin/proton-pump inhibitor treatment--a pilot study.
    Chuah SK, Tai WC, Hsu PI, Wu DC, Wu KL, Kuo CM, Chiu YC, Hu ML, Chou YP, Kuo YH, Liang CM, Chiu KW, Hu TH.
    Helicobacter; 2012 Oct; 17(5):374-81. PubMed ID: 22967121
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. A Randomized Control Trial Comparing 2 Levofloxacin-Containing Second-Line Therapies for Helicobacter pylori Eradication.
    Chuah SK, Liang CM, Lee CH, Chiou SS, Chiu YC, Hu ML, Wu KL, Lu LS, Chou YP, Chang KC, Kuo CH, Kuo CM, Hu TH, Tai WC.
    Medicine (Baltimore); 2016 May; 95(19):e3586. PubMed ID: 27175657
    [Abstract] [Full Text] [Related]

  • 6. Efficacy of 5-day levofloxacin-containing concomitant therapy in eradication of Helicobacter pylori infection.
    Federico A, Nardone G, Gravina AG, Iovene MR, Miranda A, Compare D, Pilloni PA, Rocco A, Ricciardiello L, Marmo R, Loguercio C, Romano M.
    Gastroenterology; 2012 Jul; 143(1):55-61.e1; quize e13-4. PubMed ID: 22484118
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Comparison of 10 day bismuth quadruple therapy with high-dose metronidazole or levofloxacin for second-line Helicobacter pylori therapy: a randomized controlled trial.
    Kuo CH, Hsu PI, Kuo FC, Wang SS, Hu HM, Liu CJ, Chuah SK, Chen YH, Hsieh MC, Wu DC, Tseng HH.
    J Antimicrob Chemother; 2013 Jan; 68(1):222-8. PubMed ID: 22984204
    [Abstract] [Full Text] [Related]

  • 9. Efficacy and safety of Levofloxacin, Clarithromycin and Esomeprazol as first line triple therapy for Helicobacter pylori eradication in Middle East. Prospective, randomized, blind, comparative, multicenter study.
    Assem M, El Azab G, Rasheed MA, Abdelfatah M, Shastery M.
    Eur J Intern Med; 2010 Aug; 21(4):310-4. PubMed ID: 20603042
    [Abstract] [Full Text] [Related]

  • 10. Clinical evaluation of a ten-day regimen with esomeprazole, metronidazole, amoxicillin, and clarithromycin for the eradication of Helicobacter pylori in a high clarithromycin resistance area.
    Georgopoulos SD, Xirouchakis E, Martinez-Gonzalez B, Sgouras DN, Spiliadi C, Mentis AF, Laoudi F.
    Helicobacter; 2013 Dec; 18(6):459-67. PubMed ID: 23714140
    [Abstract] [Full Text] [Related]

  • 11. Randomized Clinical Trial: Esomeprazole, Bismuth, Levofloxacin, and Amoxicillin or Cefuroxime as First-Line Eradication Regimens for Helicobacter pylori Infection.
    Fu W, Song Z, Zhou L, Xue Y, Ding Y, Suo B, Tian X, Wang L.
    Dig Dis Sci; 2017 Jun; 62(6):1580-1589. PubMed ID: 28391418
    [Abstract] [Full Text] [Related]

  • 12. Second-line levofloxacin-based triple schemes for Helicobacter pylori eradication.
    Di Caro S, Franceschi F, Mariani A, Thompson F, Raimondo D, Masci E, Testoni A, La Rocca E, Gasbarrini A.
    Dig Liver Dis; 2009 Jul; 41(7):480-5. PubMed ID: 18974025
    [Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Levofloxacin-based triple therapy in first-line treatment for Helicobacter pylori eradication.
    Nista EC, Candelli M, Zocco MA, Cremonini F, Ojetti V, Finizio R, Spada C, Cammarota G, Gasbarrini G, Gasbarrini A.
    Am J Gastroenterol; 2006 Sep; 101(9):1985-90. PubMed ID: 16968503
    [Abstract] [Full Text] [Related]

  • 16. Fourteen-day high-dose esomeprazole, amoxicillin and metronidazole as third-line treatment for Helicobacter pylori infection.
    Puig I, González-Santiago JM, Molina-Infante J, Barrio J, Herranz MT, Algaba A, Castro M, Gisbert JP, Calvet X.
    Int J Clin Pract; 2017 Sep; 71(9):. PubMed ID: 28869699
    [Abstract] [Full Text] [Related]

  • 17. Empirical modified sequential therapy containing levofloxacin and high-dose esomeprazole in second-line therapy for Helicobacter pylori infection: a multicentre clinical trial.
    Liou JM, Chen CC, Chen MJ, Chang CY, Fang YJ, Lee JY, Sheng WH, Wang HP, Wu MS, Lin JT.
    J Antimicrob Chemother; 2011 Aug; 66(8):1847-52. PubMed ID: 21632579
    [Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Randomized comparison of two rescue therapies for Helicobacter pylori infection.
    Wu DC, Hsu PI, Chen A, Lai KH, Tsay FW, Wu CJ, Lo GH, Wu JY, Wu IC, Wang WM, Tseng HH.
    Eur J Clin Invest; 2006 Nov; 36(11):803-9. PubMed ID: 17032348
    [Abstract] [Full Text] [Related]

  • 20. Efficacy of H. pylori eradication with a sequential regimen followed by rescue therapy in clinical practice.
    Pontone S, Standoli M, Angelini R, Pontone P.
    Dig Liver Dis; 2010 Aug; 42(8):541-3. PubMed ID: 20061196
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 20.